AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET
AIM ImmunoTech has rescheduled its investor conference call for January 21, 2021, at 11:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AIM ImmunoTech has rescheduled its investor conference call for January 21, 2021, at 11:00 a.m. ET. The call will focus on the amended AMP-511 trial treating patients with COVID-19-induced chronic fatigue symptoms, recent achievements, and future milestones. Interested parties can submit questions to management before the call. The conference will be accessible on AIM ImmunoTech's website, and a replay will be available for 90 days post-call. AIM is committed to developing therapeutics targeting various cancers, immune disorders, and viral diseases, including COVID-19.
Positive
- Rescheduled conference call provides a platform for discussing the AMP-511 trial.
- Focus on treatment developments for COVID-19-induced chronic fatigue patients.
- Potential to address recent achievements and future milestones, which could enhance investor confidence.
Negative
- None.
Details
News Market Reaction – AIM
The recorded move for AIM in the trading session of this news was +0.99%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones
OCALA, Fla., Jan. 15, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has rescheduled its investor conference call for 11:00 a.m. Eastern Time on Thursday, January 21, 2021 to discuss the recently announced commencement of the treatment of subjects with COVID-19-induced chronic fatigue-like symptoms in the amended AMP-511 trial, recent accomplishments and upcoming milestones.
Investors and other interested parties are invited to submit questions to management prior to the call's start via email to aim@crescendo-ir.com. Management respectfully requests that questions be non-compound, direct and addressing single subjects.
The conference call will be available on the Company’s website at https://aimimmuno.com/events-presentations/, or via telephone by dialing toll free 877-407-8031 for U.S. callers, or +1 201-689-8031 for international callers.
For those unable to participate at that time, a replay of the call will be archived on the Company’s website or can be accessed by dialing 877-481-4010 for U.S. callers, or +1 919-882-2331 for international callers and entering the pass code 39447. The replay will be available for 90 days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.
Contacts:
Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com
AIM ImmunoTech Inc.
Phone: 800-778-4042
Email: IR@aimimmuno.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.